Bristol-Myers Squibb Company Release: European Commission Approves Eliquis (Apixaban) For The Treatment Of Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE), And Prevention Of Recurrent DVT And PE

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced that the European Commission has approved Eliquis for the treatment of DVT and PE, and the prevention of recurrent DVT and PE in adults. The European Commission approval applies to all European Union (EU) member states as well as Iceland and Norway. Eliquis is also approved in the EU for the prevention of venous thromboembolism (VTE) in adults who have undergone elective total hip or knee replacement surgery, and for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors.

Help employers find you! Check out all the jobs and post your resume.